

Zelira Therapeutics Ltd

11:59 22 Aug 2019

Zelda Therapeutics achieves patient milestone in autism treatment cannabis study

Zelda Therapeutics Ltd (ASX:ZLD, FRA:G1G, OTCMKTS:ZLDAF) has enrolled a milestone 100th patient in a behavioural study evaluating its medicinal cannabis treatment in children on the autism spectrum.

The observational study at Children's Hospital of Philadelphia (CHOP) now has 103 enrolled patients whose parents are reporting on the behavioural outcomes of cannabis treatments delivered in the study.

Kids in Zelda's study are aged about 10 years old, diagnosed with autism and range in autism levels from classifications of low to medium or high-level severity.

A number of cannabis treatments are being trialled, one being THC-only, the other CBD-only or combinations of both — with a variety of dosings being studied.

Parents of the children are observing their kids' behaviour for the study and are finding improvements.

The extent of the improvements depends on the type of treatment and dosings a child is administered.

Zelda managing director Dr Richard Hopkins reported today: "We're very encouraged by the preliminary analysis of the data from this observational study.

"Results show that treatments with a range of cannabis medicines were associated with improvements in several key behavioural markers that are prominent in children diagnosed with autism.

"This highlights the potential for medicinal cannabis to improve outcomes for autistic children."

Hopkins flagged the company believes its study is the first to report what he called "differences in autism severity based on responses to medicinal cannabis treatments."

He said: "The ability to stratify patients according to various clinical criteria could help us better predict whether patients will be more likely to benefit from medicinal cannabis treatments.

"While these initial findings are encouraging, we need to be cautious interpreting the results from observational studies such as ours, where parent-reported data is used and where there is limited baseline information available prior to treatment, which can result in significant bias."

To address the potential for bias that affects reported outcomes, Zelda hopes to design a randomised blinded trial of children with autism spectrum disorder later this year.

Price: 0.047

Market Cap: \$45.42 m

1 Year Share Price Graph



Share Information

Code: ZLD

Listing: ASX

52 week High Low
0.091 0.022

Sector: Cannabis

Website: www.zeldatherapeutics.com

Company Synopsis:

Zelira Therapeutics Ltd (ASX:ZLD) is a medicinal cannabis company focused on first-in-class human clinical trials for insomnia, autism and opioid reduction.

action@proactiveinvestors.com.au

Hopkins told the market the company was well placed to be an early mover on medicinal cannabis as the pharmaceutical subsector was more regulated and prescription product requirements became more demanding clinically.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).